-
FDA approved Gylenia for children, ages 10 and older, with relapsing MS
Gilenya (fingolimod) has become the first disease-modifying therapy approved by the U.S. Food and Drug Administration (FDA) to treat children and adolescents with relapsing forms of multiple sclerosis (MS).
Read the full story at MultipleSclerosisNewsToday.com: Gilenya Approved by FDA as First DMT for Children, Ages 10 and Older, with Relapsing MS
This is great news! Do you know someone who will benefit from this medication?
-
1 Reply
-
This is a really big deal for some very important people: our youngest MS patients. Finally, there’s a DMT for them. My MS Wire column, which will post on Friday, comments on this.
Ed
Log in to reply.